Apathy in Late Life Depression: New Biomarkers Using Actimetry and Magnetic Resonance Imaging

Depression Clinical Trial

— ACTIDEP  

Official title:

Apathy in Late Life Depression: New Biomarkers Using Actimetry and Magnetic Resonance Imaging

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03807167
• Other study ID #: 35RC18_8833_ACTIDEP
• Status: Completed
• Phase: N/A
• Start date: August 9, 2019
• Est. completion date: February 9, 2023

Study information

• Verified date: March 2023
• Source: Rennes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Old age (> 60 years) is at high risk to develop major depression disorders (MDD). MDD doubles the risk for subsequent cognitive disorders and dementia. Apathy (i.e. the lack of motivation) is a core problem in depression in older age and is frequently associated with cognitive decline in people who have mild cognitive disorders. The investigator propose here to combine actimetry (the measurement of motor activity using a simple device worn at the wrist) and brain imaging to show that it's possible to measure apathy using actimetry in a population of elders with MDD. Having shown that apathy can reliably be measured with actimetry and that it is associated with brain abnormalities, the investigator will be able to test whether actimetry can predict cognitive decline in elders with MDD and can be routinely used in a day-to-day medical practice.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 102
• Est. completion date: February 9, 2023
• Est. primary completion date: February 9, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

Patients:

• 60 years and above

• Major depressive disorder (either late-onset or early onset)

• Ambulatory settings

• Both uni and bipolar depression will be considered Healthy controls

• 60 years and above

• No psychiatric disorders, including no major depressive disorder

• No non-inclusion criteria

Exclusion Criteria:

• Patients and healthy controls

• Major cognitive disorders (< 125 on the Mattis dementia rating scale and a major cognitive disorders diagnostic according to the DSM5 (Diagnostic and Statistical Manual of Mental Disorders) criteria).

• Other neurological conditions (stroke, Parkinson's disease and seizures), severe and inflammatory disorders (ex: severe arthroses which limits movements, spondylarthritis)

• Severe sarcopenia: speed walk < 1 meter/second

• Extrapyramidal syndrome

• High suicidal risk

• Anti-psychotic prescription

• Participant who are unable to provide clear consent, under legal protection

• MRI contra-indication

Related Conditions & MeSH terms

• Depression
• Depressive Disorder

Intervention

Other:
• Mattis Dementia Rating Scale
This scale was developed to assess the cognitive status of patients with neurodegenerative diseases. There are 37 items that are presented in a fixed order and grouped into five sub-scales: attention, initiation, construction, conceptualization and memory. Patients and healthy subjects with a score below 125 are not included because of major cognitive impairment.
• Unified Parkinson 's Disease Rating Scale-III
This scale is used to rate the severity of extra-pyramidal symptoms (akinesia, rigidity and tremors). These symptoms may be the cause of reduction of motor activity apart from any reduction in motivation, they onstitute a confounding factor that it should be controlled.
• Mini Neuropsychiatric Investigation
This is a structured interview that allows rapid screening in about 20 minutes of troubles Psychiatric. It is based on short questions to which the patient must answer yes or no and on a decision tree. Patients must validate clinical diagnoses of depression.
• Montgomery and Asberg depression Rating Scale
This scale is composed of 10 items from 0 to 6 from a semi-structured interview, to obtain a total depression score of 0 to 60 (0 no depression, 60 maximum intensity of depression).
• Clinical Global Impression
heterosexual assessment that rates the severity of symptoms suicidal and changes in suicidal symptoms. Any subject with a score greater than 4 is not included.
• Apathy diagnostic criteria
The clinical criteria make it possible to make a diagnosis of apathy with a functional repercussion. It is based on a lack of motivation felt by the patient, causing a functional or social impact that is not the consequence of a disturbance of consciousness or a disability engine. The cognitive, emotional and behavioral dimensions are affected.
• walking speed test
The patient is timed to walk 10m. A speed <1m / sec is a criterion exclusion because it shows severe sarcopenia and constitutes a bias.
• accelerometer presentation
accelerometer presentation and pose
• data acquisition from the accelerometer
withdrawal of the accelerometer and data acquisition from the accelerometer
• Apathy Evaluation Scale,
clinician version and near-helping version. It's a hetero rating scale from an interview semi structured by a trained clinician. It assesses cognitive, emotional and behavioral apathy than three items of various apathy. The total score ranges from 18 (total absence of apathy) to 72.
• fatigue Visual Analog Scale
To date, there is no valid fatigue scale in the depression of the elderly subject, a fortiori in French. The fatigue scale in adult depression includes has been validated with an EVA (Visual Analogue Scale) (38). We therefore propose to use this type of evaluation to control this aspect.
• executive function
Modified Card Sorting Test MCST(Modified Card Sorting Test) (Wisconsin Test): This test assesses conceptualization, attention and mental flexibility using a deck of cards. Trail Making Test (TMT): This test is used to assess mental flexibility. Fluences verbal: This test tests the capacities of setting up search strategies in memory semantics and oral language. Stroop Paradigm: This test is used to evaluate the resistance to interference, ie the patient's ability to inhibit some over-learned and automated responses.
• MRI
An MRI lasting 30 minutes is programmed
• Apathy Motivation Index
This is a self-questionnaire of 18 items, each side on a 5-level Likert scale (0: not everything at 4: very often). It differentiates between "behavioral" apathy and "social" apathy. "Emotional".

Locations

Country	Name	City	State
France	Centre Mémoire de Ressources et de Recherche (CMRR),	Nice
France	Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte	Rennes
France	CHU Pontchaillou, Département de Radiologie et d'Imagerie Médicale	Rennes
France	CHU Bretonneau, Consultations Intersectorielles de Gérontopsychiatrie	Tours
France	CHU Bretonneau,CIC	Tours
France	Service de Radiologie- Neuroradiologie,CHU bretonneau	Tours

Sponsors (1)

Lead Sponsor	Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Actimetry	Measure of actimetry: immobility, transfer, walking, movement given by the accelerometer	3 days
Secondary	grey matter density	Magnetic Resonance Imaging brain metrics: grey matter density	at Day 3 (+/- 2 days)
Secondary	cortical thickness	Magnetic Resonance Imaging brain metrics: cortical thickness;	at Day 3 (+/- 2 days)
Secondary	diffusion tensor imaging,	Magnetic Resonance Imaging brain metrics: diffusion tensor imaging,	at Day 3 (+/- 2 days)
Secondary	Rest functional connectivity analysis	Magnetic Resonance Imaging brain metrics: regional cerebral blood flow	at Day 3 (+/- 2 days)
Secondary	pulsatility.	Magnetic Resonance Imaging brain metrics: pulsatility.	at Day 3 (+/- 2 days)